Miami, FL, June 24, 2002
Noven Appoints Karen Frank, MD As Vice President of Clinical Research & Regulatory Affairs
-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced the appointment of Karen A. Frank, MD as its Vice President – Clinical Research & Regulatory Affairs. Dr. Frank will report to Robert C. Strauss, Noven's President, CEO & Chairman, and will be responsible for overseeing Noven's clinical operations and for providing medical and regulatory direction for the company.
Prior to joining Noven, Dr. Frank was a member of the clinical research and development team at Novartis Pharmaceuticals of East Hanover, New Jersey, where she developed clinical development plans for new chemical entities and provided oversight of Phase II-IV clinical trials. Previously, she led clinical science efforts at Roche Group in Basel, Switzerland, and designed and conducted clinical trials for Monsanto Pharma/GD Searle in Chicago, Illinois.
Before entering the private sector, Dr. Frank served as a medical officer at the U.S. Food and Drug Administration's Center for Drug Evaluation & Research in Rockville, Maryland. At the FDA, Dr. Frank's responsibilities included reviewing New Drug Applications and Investigational New Drug Applications and addressing class labeling and advertising issues.
"Dr. Frank joins Noven's clinical and regulatory group at a very busy and exciting time," said Robert Strauss. "We expect to be submitting our New Drug Application for MethyPatch® on schedule this summer, entering new clinical trials this year, and monitoring ongoing clinical trials by third parties for Noven patch products in foreign markets. Karen's experience at the FDA and with large-scale clinical trial programs on both sides of the Atlantic will be invaluable to these efforts, and positions her as an important contributor to the success of Noven's pipeline products."
Dr. Frank earned her MD from the Johns Hopkins University School of Medicine. After internship and residency at Washington University School of Medicine, she completed board certification in internal medicine. She received fellowship training in drug development in a program sponsored jointly by the U.S. Food and Drug Administration and Georgetown University School of Medicine. She earned her BS in chemistry from Wheaton College.
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a highly profitable women's health products company called Novogyne Pharmaceuticals. Noven's existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot®, licensed to Novogyne, and Estradot®, licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch®, licensed to Novogyne, and Estalis®, licensed to Novartis Pharma AG). With a range of additional products in development, including MethyPatch®, Noven is committed to becoming the world's premier developer, manufacturer and marketer of transdermal drug delivery systems. For additional information on Noven, visit http://www.noven.com.
This release contains forward-looking statements related to the business of Noven that can be identified by the use of forward-looking terminology such as "expects" and similar words and phrases. Such statements are qualified by and subject to the risks and uncertainties specified in Noven's most recent filings with the Securities and Exchange Commission and in this press release, including the risk that the MethyPatch NDA may not be filed in a timely fashion, that new U.S. clinical trials may not commence on schedule, that clinical trials in foreign markets may be discontinued, and that any given clinical development project may not result in an approved and commercialized product.
Investor & Media Contact:
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.